No­vo Nordisk of­floads pre­clin­i­cal can­cer can­di­date from $1.1B For­ma buy­out

When No­vo Nordisk first ap­proached For­ma Ther­a­peu­tics about a deal, the Dan­ish drug­mak­er made clear that it was re­al­ly on­ly in­ter­est­ed in For­ma’s sick­le cell drug etavopi­vat. Even though For­ma ul­ti­mate­ly con­vinced No­vo to buy the whole com­pa­ny — com­plete with a slate of on­col­o­gy pro­grams — for $1.1 bil­lion, No­vo isn’t keep­ing all of them around.

Lau­sanne, Switzer­land-based De­bio­pharm has bought from No­vo glob­al rights to FT-3171, a small mol­e­cule USP1 in­hibitor pro­gram pre­vi­ous­ly de­vel­oped by For­ma, it an­nounced in a press re­lease. No fi­nan­cials were pro­vid­ed.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER